Background: Currently, the axillary management strategy of omitting axillary lymph node dissection (ALND) in early-stage breast cancer (BC) patients with cT1-2, clinically node-negative (cN0), and ...

Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: A systematic review and meta-analysis. This ...

Division of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea Purpose: With the advancement of neoadjuvant chemotherapy (NAC ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...

Sentinel lymph node biopsy has replaced traditional axillary dissection, minimizing lymphedema risk in breast cancer surgery. The procedure targets the first draining lymph nodes, reducing unnecessary ...

Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

1. The hazard ratio for recurrence or death comparing sentinel node biopsy only to completion axillary lymph node dissection was non-significant (0.89) and below the noninferiority margin. 2. The ...

1. The hazard ratio for recurrence or death comparing sentinel node biopsy only to completion axillary lymph node dissection was non-significant (0.89) and below the noninferiority margin. 2. The ...

THURSDAY, April 4, 2024 (HealthDay News) -- For patients with clinically node-negative breast cancer with sentinel-node macrometastases, the omission of completion axillary-lymph-node dissection is ...